

Docket No.: 04654/1200494-US1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Balasubramanian Gopalan et al.

Application No.: 10/821,642

Confirmation No.: 9007

Examiner: Y. L. Chu

Filed: April 9, 2004

Art Unit: 1626

For: NOVEL HETEROCYCLIC COMPOUNDS

USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC **DISORDERS: PROCESS FOR THEIR**

PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

<u>INFORMATION DISCLOSURE STATEMENT (IDS)</u>

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, attached hereto is a copy of Form PTO/SB/08 and copies of the documents listed thereon (except for copies of the issued U.S. patents).

U.S. Patent No. 3,846,553 is the U.S. counterpart to German Patent Publication No. 2059358, which was cited in the August 20, 2004 Information Disclosure Statement.

U.S. Serial No. 10/532,273 (citation AB) is a co-pending application which has three common inventors with the present application. U.S. Serial No. 10/532,273 is a national phase of and, therefore, has the same specification as International Publication No. WO 2004/037805 (citation BD). A copy of International Publication No. WO 2004/037805 is submitted herewith.

05/02/2006 TLUU11 00000003 10821642

02 FC:1806

180.00 OP

Therefore, applicants respectfully submit that the requirement under 37 CFR 1.98(a)(2)(iii) for a copy of the specification, claims, and drawings of U.S. Serial No. 10/532,273 has been satisfied.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document

cited (including any cited in applicant's specification which is not repeated on the attached Form

PTO/SB/08) be given thorough consideration and that it be cited of record in the prosecution history

of the present application by initialing Form PTO/SB/08 next to the document. Such initialing is

requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use

in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner

does not believe that the guidelines for citation have been fully complied with. This is requested so

that each document becomes listed on the face of the patent issuing on the present application.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement

shall not be construed to mean that a search has been made or that no other material information as

defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information

Disclosure Statement shall not be construed to be an admission that any patent, publication or other

information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR

1.98 and the Examiner is respectfully requested to consider the listed references.

Submitted herewith is the fee of \$180 required with this IDS. The Commissioner is

authorized to charge any deficiency of up to \$2,000.00 or credit any excess in this fee to Deposit

Account No. 04-0100.

Dated: April 28, 2006

Respectfully submitted,

Registration No.: 41,151

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

2

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	10/821,642-Conf. #9007	
INF	ORMATI	ON DISC	CLOSURE	Filing Date	April 9, 2004	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Balasubramanian Gopalan	
				Art Unit	1626	
(Use as many sheets as necessary)			cessary)	Examiner Name	Y. L. Chu	
Sheet	1	of	1	Attorney Docket Number	04654/1200494-US1	

U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY		Figures Appear
	AA	3,846,553	11-05-1974	Shen et al.	
	AB	10/532,273		Balasubramanian et al.	
	AC	6,110,962	08/29/2000	Wrobel et al.	

	FOREIGN PATENT DOCUMENTS						
	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
	BA	WO 99/58521	11-18-1999	American Home Products			
				Corp.			
	BB	WO 96/03377	02-08-1996	Sankyo Company, Limited			
	BC	JP 63 014156	06-21-1988	Canon Inc.			
	BD	WO 2004/037805	05-06-2004	Glenmark Pharmaceuticals			
				Ltd.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA	NIELSEN, K.F. et al, Fungal metabolite screening: database of 474 mycotoxins and fungal metabolites for dereplication by standardised liquid chromatography-UV-mass spectrometry methodology. <i>Journal of Chromatography</i> 1002, 1-2:111-136		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	 Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.